TAO Synergies Inc 8-K, filed Jun 22, 2023
TAO Synergies Inc. (TAOX)
About this 8-K
TAO Synergies Inc filed this 8-K on June 22, 2023, reporting on events of June 16, 2023.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
(Address of principal executive offices and zip code)
Registrant’s telephone number, including
area code: (
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company.
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 5.02. |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
As previously disclosed, on December 7, 2020, Synaptogenix, Inc. (the “Company”) entered into an offer letter with Alan J. Tuchman, M.D., pursuant to which Dr. Tuchman agreed to serve as the Company’s Chief Executive Officer, and such letter was amended on August 4, 2022 to extend the term of Dr. Tuchman’s employment through June 7, 2023 (as amended, the “Offer Letter”). On June 16, 2023, the Company entered into a second amendment to the Offer Letter (the “Second Amendment”) to extend the term of Dr. Tuchman’s employment through June 7, 2024, with automatic monthly renewals thereafter unless earlier terminated in accordance with the terms of the Second Amendment.
The foregoing description of the Second Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Second Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit | Description |
| 10.1 | Amendment to the offer letter, dated June 16, 2023, by and between the Company and Alan J. Tuchman, M.D. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SYNAPTOGENIX, INC. |
| Date: June 22, 2023 | By: | /s/ Robert Weinstein |
| Name: | Robert Weinstein | |
| Title: | Chief Financial Officer |
Exhibit 10.1
June 16, 2023
Personal and Confidential
Re: Amendment No. 2 to Offer Letter
Dear Alan:
This Amendment No. 2 to the Offer Letter (this “Amendment”) will serve to implement certain changes to your Offer Letter with Synaptogenix Inc. (the “Company”), dated December 7, 2020, as amended August 4, 2022 (the “Offer”). This Amendment is effective as of June 7, 2023. Capitalized terms used but not defined herein shall have the meaning attributed by the Offer.
1. Term. Section 2 of the Offer is deleted in its entirety and replaced with the following:
“2. Term. Your employment pursuant to this Offer commenced on December 7, 2020 (the “Effective Date”) and shall continue until June 7, 2024 (the “Term”); provided the Term shall be automatically extended for successive one (1) month periods unless either party gives written notice to the other party at least seven (7) days prior to the end of the applicable Term. Notwithstanding the foregoing, the Company may terminate this Offer on seven (7) days written notice to you.”
2. Section 409A. The following Section 14 shall be added to the Offer:
“14. Section 409A. Notwithstanding anything herein to the contrary, this Offer is intended to be interpreted and applied so that the payment of the benefits set forth herein either shall be exempt from the requirements of Section 409A (“Section 409A”) of Internal Revenue Code of 1986, as amended (the “Code”) and the regulations thereunder or shall comply with the requirements of Section 409A. Notwithstanding anything in this Offer or elsewhere to the contrary, payments upon termination of the your employment that constitute a “deferral of compensation” within the meaning of Section 409A may only be made upon a “separation from service” as determined under Section 409A. Each payment under this Offer or otherwise shall be treated as a separate payment for purposes of Section 409A. In no event may you, directly or indirectly, designate the calendar year of any payment to be made under this Offer or otherwise which constitute a “deferral of compensation” within the meaning of Section 409A. Notwithstanding any provision in this Offer to the contrary, if on the date of separation from service you are deemed to be a “specified employee” within the meaning of Section 409A using the identification methodology selected by the Company from time to time, or if none, the default methodology under Section 409A, any payments or benefits due upon a termination of your employment under any arrangement that constitutes a “deferral of compensation” within the meaning of Section 409A shall be delayed and paid or provided (or commence, in the case of installments) on the first payroll date on or following the earlier of (i) the date which is six (6) months and one (1) day after your date of termination for any reason other than death, and (ii) the date of your death, and any remaining payments and benefits shall be paid or provided in accordance with the normal payment dates specified for such payment or benefit. Notwithstanding any of the foregoing to the contrary, the Company and its respective officers, directors, employees, or agents make no guarantee that the terms of this Offer as written comply with, or are exempt from, the provisions of Section 409A, and none of the foregoing shall have any liability for the failure of the terms of this Offer as written to comply with, or be exempt from, the provisions of Section 409A.”
3. Section 280G. The following Section 15 shall be added to the Offer:
“15. Section 280G. In the event you become entitled to any benefits or payments in the nature of compensation (within the meaning of Section 280G(b)(2) of the Code) under this Offer, or any other plan, arrangement, or agreement with the Company (the “Payments”), and such benefits or payments would (in the absence of this Section 15) be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), the aggregate present value of the Payments shall be reduced (but not below zero) to the Reduced Amount (as defined below), if reducing the Payments will provide you with a greater net after tax amount than would be the case if no reduction was made. The “Reduced Amount” shall be an amount expressed in present value which maximizes the aggregate present value of Payments without causing any Payment to be subject to the Excise Tax, determined in accordance with Section 280G(d)(4) of the Code. If Payments are to be reduced, the Company shall reduce the Payments by first reducing Payments that are payable in cash and then by reducing non-cash Payments. All determinations to be made under this Section 15 shall be made by the Company’s independent public accounting firm as in effect immediately prior to the event that constitutes a change in control under Section 280G of the Code or another independent firm selected by the Company before such event (the “Accounting Firm”). Any such determination by the Accounting Firm shall be binding upon the Company and you. All of the fees and expenses of the Accounting Firm in performing the determinations referred to in this Section 15 shall be borne solely by the Company.”
4. No Other Changes. Except as expressly set forth in this Amendment, there have been no other changes or modifications to the Offer, and the Offer remains otherwise unchanged and in full force and effect.
You may accept this Amendment by countersigning below where indicated and returning it to me.
| Best Regards, | ||
| Synaptogenix Inc. | ||
| /s/ Robert Weinstein | ||
| Name: Robert Weinstein | ||
| Title: Chief Financial Officer |
| Agreed to and Accepted: | |
| /s/ Dr. Alan J. Tuchman | |
| Dr. Alan J. Tuchman | |
| Date: June 16, 2023 |